R-spondin1, A Novel Intestinotrophic Mitogen, Ameliorates Experimental Colitis in Mice

Gastroenterology

Volumn 132, Issue 4, 2007, Pages 1331-1343

  Zhao, Jingsong ^a   de Vera, Josephine ^a   Narushima, Seiko ^b   Beck, Eric X ^a   Palencia, Servando ^a   Shinkawa, Pauline ^a   Kim, Kyung Ah ^a   Liu, Yi ^a   Levy, Michael D ^a   Berg, Daniel J ^b   Abo, Arie ^a   Funk, Walter D ^a  

^a Nuvelo Inc   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXTRAN SULFATE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; MITOGENIC AGENT; PIROXICAM; R SPONDIN1; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CYTOKINE PRODUCTION; DIARRHEA; DISEASE SEVERITY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; INFLAMMATION; INTESTINE CRYPT; INTESTINE MUCOSA; INTESTINE VILLUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RECTUM HEMORRHAGE; TISSUE REGENERATION; WEIGHT REDUCTION;

EID: 34247193001     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2007.02.001     Document Type: Article

References (50)

1. Kamata T., Katsube K., Michikawa M., Yamada M., Takada S., and Mizusawa H. R-spondin, a novel gene with thrombospondin type 1 domain, was expressed in the dorsal neural tube and affected in Wnts mutants. Biochim Biophys Acta 1676 (2004) 51-62
2. Kazanskaya O., Glinka A., del Barco Barrantes I., Stannek P., Niehrs C., and Wu W. R-Spondin2 is a secreted activator of Wnt/beta-catenin signaling and is required for Xenopus myogenesis. Dev Cell 7 (2004) 525-534
3. Kim K.A., Kakitani M., Zhao J., Oshima T., Tang T., Binnerts M., Liu Y., Boyle B., Park E., Emtage P., Funk W.D., and Tomizuka K. Mitogenic influence of human R-spondin1 on the intestinal epithelium. Science 309 (2005) 1256-1259
4. Bouma G., and Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3 (2003) 521-533
5. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
6. Radtke F., and Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science 307 (2005) 1904-1909
7. Stainier D.Y. No organ left behind: tales of gut development and evolution. Science 307 (2005) 1902-1904
8. Holmberg J., Genander M., Halford M.M., Anneren C., Sondell M., Chumley M.J., Silvany R.E., Henkemeyer M., and Frisen J. EphB receptors coordinate migration and proliferation in the intestinal stem cell niche. Cell 125 (2006) 1151-1163
9. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120 (2001) 622-635
10. Lim W.C., and Hanauer S.B. Emerging biologic therapies in inflammatory bowel disease. Rev Gastroenterol Disord 4 (2004) 66-85
11. Boushey R.P., Yusta B., and Drucker D.J. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 277 (1999) E937-E947
12. Drucker D.J., Yusta B., Boushey R.P., DeForest L., and Brubaker P.L. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 276 (1999) G79-G91
13. Egger B., Procaccino F., Sarosi I., Tolmos J., Buchler M.W., and Eysselein V.E. Keratinocyte growth factor ameliorates dextran sodium sulfate colitis in mice. Dig Dis Sci 44 (1999) 836-844
14. Miceli R., Hubert M., Santiago G., Yao D.L., Coleman T.A., Huddleston K.A., and Connolly K. Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J Pharmacol Exp Ther 290 (1999) 464-471
15. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., Schaible T.F., and van Deventer S.J. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
16. Travassos W.J., and Cheifetz A.S. Infliximab: Use in inflammatory bowel disease. Curr Treat Options Gastroenterol 8 (2005) 187-196
17. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., and Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98 (1990) 694-702
18. Murthy S.N., Cooper H.S., Shim H., Shah R.S., Ibrahim S.A., and Sedergran D.J. Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38 (1993) 1722-1734
19. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., and Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182 (1995) 1281-1290
20. Wallace J.L., MacNaughton W.K., Morris G.P., and Beck P.L. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96 (1989) 29-36
21. Bouma G., Kaushiva A., and Strober W. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterology 123 (2002) 554-565
22. Katz J.P., Perreault N., Goldstein B.G., Lee C.S., Labosky P.A., Yang V.W., and Kaestner K.H. The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development 129 (2002) 2619-2628
23. Berg D.J., Zhang J., Weinstock J.V., Ismail H.F., Earle K.A., Alila H., Pamukcu R., Moore S., and Lynch R.G. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology 123 (2002) 1527-1542
24. Berg D.J., Davidson N., Kuhn R., Muller W., Menon S., Holland G., Thompson-Snipes L., Leach M.W., and Rennick D. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 98 (1996) 1010-1020
25. Krieglstein C.F., Cerwinka W.H., Sprague A.G., Laroux F.S., Grisham M.B., Koteliansky V.E., Senninger N., Granger D.N., and de Fougerolles A.R. Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J Clin Invest 110 (2002) 1773-1782
26. Rogler G., and Andus T. Cytokines in inflammatory bowel disease. World J Surg 22 (1998) 382-389
27. Papadakis K.A., and Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51 (2000) 289-298
28. Papadakis K.A., and Targan S.R. The role of chemokines and chemokine receptors in mucosal inflammation. Inflamm Bowel Dis 6 (2000) 303-313
29. Stopfer P., Obermeier F., Dunger N., Falk W., Farkas S., Janotta M., Moller A., Mannel D.N., and Hehlgans T. Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis. Clin Exp Immunol 136 (2004) 21-29
30. Elson C.O., Sartor R.B., Tennyson G.S., and Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology 109 (1995) 1344-1367
31. Gurtner G.J., Newberry R.D., Schloemann S.R., McDonald K.G., and Stenson W.F. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 125 (2003) 1762-1773
32. Rosner A., Miyoshi K., Landesman-Bollag E., Xu X., Seldin D.C., Moser A.R., MacLeod C.L., Shyamala G., Gillgrass A.E., and Cardiff R.D. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 161 (2002) 1087-1097
33. Yusta B., Estall J., and Drucker D.J. Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem 277 (2002) 24896-24906
34. Nam J.S., Turcotte T.J., Smith P.F., Choi S., and Yoon J.K. Mouse cristin/R-spondin family proteins are novel ligands for the Frizzled 8 and LRP6 receptors and activate beta-catenin-dependent gene expression. J Biol Chem 281 (2006) 13247-13257
35. Stadnicki A., and Colman R.W. Experimental models of inflammatory bowel disease. Arch Immunol Ther Exp (Warsz) 51 (2003) 149-155
36. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., and Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 (2006) 677-688
37. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., Kleinschek M.A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D.J., Kastelein R.A., and Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 116 (2006) 1310-1316
38. Sasaki M., Mathis J.M., Jennings M.H., Jordan P., Wang Y., Ando T., Joh T., and Alexander J.S. Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector. J Inflamm (Lond) 2 (2005) 13
39. Kuhn R., Lohler J., Rennick D., Rajewsky K., and Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75 (1993) 263-274
40. Davidson N.J., Hudak S.A., Lesley R.E., Menon S., Leach M.W., and Rennick D.M. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 161 (1998) 3143-3149
41. Wittig B.M., Johansson B., Zoller M., Schwarzler C., and Gunthert U. Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J Exp Med 191 (2000) 2053-2064
42. Mahler M., and Leiter E.H. Genetic and environmental context determines the course of colitis developing in IL-10-deficient mice. Inflamm Bowel Dis 8 (2002) 347-355
43. Rennick D.M., and Fort M.M. Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 278 (2000) G829-G833
44. Myers K.J., Murthy S., Flanigan A., Witchell D.R., Butler M., Murray S., Siwkowski A., Goodfellow D., Madsen K., and Baker B. Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. J Pharmacol Exp Ther 304 (2003) 411-424
45. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J., and Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337 (1997) 1029-1035
46. Kim K.A., Zhao J., Andarmani S., Kakitani M., Oshima T., Binnerts M.E., Abo A., Tomizuka K., and Funk W.D. R-Spondin proteins: a novel link to beta-catenin activation. Cell Cycle 5 (2006) 23-26
47. Parma P., Radi O., Vidal V., Chaboissier M.C., Dellambra E., Valentini S., Guerra L., Schedl A., and Camerino G. R-spondin1 is essential in sex determination, skin differentiation and malignancy. Nat Genet 38 (2006) 1304-1309
48. Capel B. R-spondin1 tips the balance in sex determination. Nat Genet 38 (2006) 1233-1234
49. Blaydon D.C., Ishii Y., O'Toole E.A., Unsworth H.C., Teh M.T., Ruschendorf F., Sinclair C., Hopsu-Havu V.K., Tidman N., Moss C., Watson R., de Berker D., Wajid M., Christiano A.M., and Kelsell D.P. The gene encoding R-spondin 4 (RSPO4), a secreted protein implicated in Wnt signaling, is mutated in inherited anonychia. Nat Genet 38 (2006) 1245-1247
50. Nam J.S., Turcotte T.J., and Yoon J.K. Dynamic expression of R-spondin family genes in mouse development. Gene Expr Patterns 3 (2007) 306-312